In the past week, HBIO stock has gone up by 2.43%, with a monthly gain of 59.36% and a quarterly plunge of -18.53%. The volatility ratio for the week is 1.81%, and the volatility levels for the last 30 days are 23.86% for Harvard Bioscience Inc The simple moving average for the last 20 days is 15.20% for HBIO stock, with a simple moving average of -64.49% for the last 200 days.
Is It Worth Investing in Harvard Bioscience Inc (NASDAQ: HBIO) Right Now?
Moreover, the 36-month beta value for HBIO is 1.55. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for HBIO is 37.41M and currently, short sellers hold a 17.76% of that float. On June 20, 2025, HBIO’s average trading volume was 11.55M shares.
HBIO) stock’s latest price update
Harvard Bioscience Inc (NASDAQ: HBIO) has seen a rise in its stock price by 9.90 in relation to its previous close of 0.49. However, the company has experienced a 2.43% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-02 that HOLLISTON, Mass., June 02, 2025 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the appointment of John Duke to its board of directors, effective June 2, 2025. Mr. Duke will also serve on the audit and nominating and governance committees. The Company also announced that Katherine Eade has been named Lead Independent Director of the Company’s board of directors.
Analysts’ Opinion of HBIO
The Benchmark Company, on the other hand, stated in their research note that they expect to see HBIO reach a price target of $4, previously predicting the price at $3. The rating they have provided for HBIO stocks is “Buy” according to the report published on March 10th, 2023.
HBIO Trading at 32.99% from the 50-Day Moving Average
After a stumble in the market that brought HBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.11% of loss for the given period.
Stock Fundamentals for HBIO
Current profitability levels for the company are sitting at:
- -0.48 for the present operating margin
- 0.56 for the gross margin
The net margin for Harvard Bioscience Inc stands at -0.64. The total capital return value is set at -1.81. Equity return is now at value -138.80, with -54.52 for asset returns.
Based on Harvard Bioscience Inc (HBIO), the company’s capital structure generated 0.33 points at debt to capital in total, while cash flow to debt ratio is standing at 0.42. The debt to equity ratio resting at 0.49. The interest coverage ratio of the stock is -26.43.
Currently, EBITDA for the company is -1.47 million with net debt to EBITDA at -0.04. When we switch over and look at the enterprise to sales, we see a ratio of 0.27. The receivables turnover for the company is 6.78for trailing twelve months and the total asset turnover is 1.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.81.
Conclusion
To wrap up, the performance of Harvard Bioscience Inc (HBIO) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
